Financing issues have little to do with Nader and mostly to do with what the debt / equity market will offer to a BioTech with zero revenue. CYDY's management team executes at the direction of the BOD. While I do not like the dilution, it is a necessary "evil". Let's not blame the messenger (Management). As long as we get to the "finish line", whether BO or JV or Licensing, etc. I'm good with it.